Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients

Therapeutic Apheresis and Dialysis

Volumn 15, Issue 6, 2011, Pages 547-555

  El Shafey, Eid M ^a,c   Alsahow, Ali E ^c   Alsaran, Khalid ^d   Sabry, Alaa A ^d   Atia, Mohamed ^b  

^a TANTA UNIVERSITY   (Egypt)

^b TANTA UNIVERSITY   (Egypt)

^c Jahra Hospital   (Kuwait)

^d Prince Salman Center for Kidney Disease   (Saudi Arabia)

Author keywords

Cinacalcet HCl; Hemodialysis; K DOQI guidelines; Outcomes; Secondary hyperparathyroidism

Indexed keywords

ALFACALCIDOL; CALCIUM; CINACALCET; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS; SEVELAMER; VITAMIN D;

ADULT; AGED; ALLOPATHY; ARTICLE; BONE DENSITY; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFICACY; DYSPEPSIA; FEMALE; FEMUR; HEMODIALYSIS PATIENT; HUMAN; HYPOCALCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SECONDARY HYPERPARATHYROIDISM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; X RAY ABSORPTION SPECTROSCOPY;

ABSORPTIOMETRY, PHOTON; ADULT; AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CHELATING AGENTS; FEMALE; FEMUR; HUMANS; HYPERPARATHYROIDISM, SECONDARY; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; NAPHTHALENES; PHOSPHORUS; PROSPECTIVE STUDIES; PRURITUS; RENAL DIALYSIS; TREATMENT OUTCOME; VITAMIN D;

EID: 82155184314     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2011.00994.x     Document Type: Article

References (22)

1. Owda A, Elhwairis H, Narra S, Towery H, Osama S. Secondary hyperparathyroidism in chronic hemodialysis patients: prevalence and race. Ren Fail 2003;25:595-602.
2. Block GA, Martin KJ, de Francisco ALM etal. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004;350:1516-25.
3. Ganesh SK, Stack AG, Levin NW etal. Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001;12:2131-8.
4. Marco MP, Craver L, Betriu A etal. Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population. Kidney Int 2003;85(Suppl):S111-14.
5. Block GA, Klassen PS, Lazarus JM etal. Mineral metabolism, mortality and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-18.
6. Young EW, Albert JM, Satayathum S etal. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005;67:1179-87.
7. Eknoyan G, Levin A, Levin N. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis 2003;42(Suppl 3):S1-201.
8. Drüeke TB. Modulation and action of the calcium-sensing receptor. Nephrol Dial Transplant 2004;19(Suppl 5):20-6.
9. 2+ for drug development: the extracellular calcium receptor and an innovative medical approach to control secondary hyperparathyroidism by calcimimetics. J Pharmacol Sci 2005;97:355-60.
10. Lindberg JS, Culleton B, Wong G etal. Cinacalcet HCl, an oral calcimimetics agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized double-blind, multicenter study. J Am Soc Nephrol 2005;16:800-7.
11. Psieka JL, Parsons LL. A prospective surgical outcome study assessing the impact of parathyroidectomy on symptoms in patients with secondary and tertiary hyperparathyroidectomy. Surgery 2001;128:531-9.
12. Young EW, Akiba T, Albert JM etal. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Am J Kidney Dis 2004;44:S34-8.
13. Sterrett JR, Strom J, Stummvoll H-K etal. Cinacalcet HCl (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol 2007;68:10-7.
14. Piergiorgio M, Fernando M, Magdi Y etal. The OPTIMA Study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 2008;3:36-45.
15. Chertow GM, Blumenthal S, Turner S etal. Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D or its analogues with controlled PTH and elevated calcium phosphate. Clin J Am Soc Nephrol 2006;1:305-12.
16. Schober HC, Han ZH, Foldes AJ etal. Mineralized bone loss at different sites in dialysis patients: implications for prevention. J Am Soc Nephrol 1998;9:1225-33.
17. Lien YH, Silva AL, Whittman D. Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2005;20:1232-7.
18. Smržová J, Urbánek T. Cinacalcet-clinical and laboratory effectiveness, concomitant treatment patterns and treatment cost: could we do better and how? Kidney Blood Press Res 2010;33:333-42.
19. Cunningham J, Danese M, Olson K etal. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005;68:1793-800.
20. Colloton M, Shatzen E, Miller G etal. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int 2005;67:467-76.
21. Wada M, Furuya Y, Kobayashi N etal. The calcimimetic compound, cinacalcet HCl, ameliorates osteitis fibrosa in rats with chronic renal insufficiency. J Bone Miner Res 2003;18:S99.
22. Moe SM, Chertow GM, Coburn JW. Achieving NKF-K/DOQI bone metabolism and treatment goals with cinacalcet HCl. Kidney Int 2005;67:760-71.